Evidence map›Paper›PMID 42631674›Full record

ArticleJACC. Case reports2026

Severe Multivessel Coronary Artery Disease in an Adolescent With Genetic Dyslipidemia.

Venessa Thorsen, George Slim, Navaneetha Saskikumar, Kevin R Bainey, Anita Y M Chan, Robert A Hegele, Michael Khoury

Abstract readCase Reports
In one paragraph

Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Venessa ThorsenFaculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.
George SlimFaculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada; Stollery Children's Hospital, Edmonton, Alberta, Canada.
Navaneetha SaskikumarFaculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada; Stollery Children's Hospital, Edmonton, Alberta, Canada; Mazankowski Alberta Heart Institute, Edmonton, Alberta, Canada.
Kevin R BaineyFaculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada; Mazankowski Alberta Heart Institute, Edmonton, Alberta, Canada.
Anita Y M ChanFaculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada; Mazankowski Alberta Heart Institute, Edmonton, Alberta, Canada.
Robert A HegeleDepartment of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
Michael KhouryFaculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada; Stollery Children's Hospital, Edmonton, Alberta, Canada. Electronic address: khoury1@ualberta.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFamilial hypercholesterolemia is characterized by lifelong elevations in low-density lipoprotein cholesterol (LDL-C) that, when left untreated, markedly increase the risk of premature atherosclerotic cardiovascular disease (ASCVD). Although ASCVD is common in adults with familial hypercholesterolemia, events in adolescence are rare. CASE SUMMARY: A 14-year-old man presented with exertional chest pain and mild troponin elevation. Myocarditis was initially suspected, but the persistence of symptoms prompted advanced imaging, revealing multivessel ASCVD. LDL-C was severely elevated (9 mmol/L, 350 mg/dL). Atorvastatin and ezetimibe lowered LDL-C to ≤1.4 mmol/L (<55 mg/dL). Multivessel percutaneous coronary intervention resulted in resolution of symptoms and inducible ischemia. A heterozygous APOE p.(Leu167del) pathogenic variant was identified, an uncommon cause of heterozygous familial hypercholesterolemia (HeFH). Similarly severe dyslipidemia was identified in the 6-year-old brother. DISCUSSION: This particularly aggressive and genetically unique form of HeFH resulted in premature ASCVD from adolescence. TAKE-HOME MESSAGE: Early detection and treatment prevent catastrophic cardiovascular events in HeFH; cascade screening is essential for at-risk relatives.

Indexed as

atherosclerosiscardiovascular diseasedyslipidemiasgenetic disorderslipid metabolism disorderspercutaneous coronary interventionstents

Identifiers

PMID42631674
PMCPMC13643450

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.